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Abstract
Hazardous drug exposure in healthcare is a growing concern for the pharma industry and workers.
Significant risks may be present including cancers for those handling and compounding various
therapeutic agents. Workplace exposure standards do not exist for those employed in the pharma
industry. Recommendations of safety have used the, ‘As Low as Reasonably Achievable’ (ALARA)
principle to control exposures for pharmacists and others that handle hazardous substances. Steps should
be taken to systematically eliminate and/or minimize exposures to workers through safer handling
protocols, approved safety cabinets, negative pressure rooms, local exhaust ventilation, health
surveillance, training and appropriate PPE.

Key words: Hazardous drugs. Antineoplastic drugs. Oncology. Pharmacy industry. Drug safety. ISOPP
standards.

Introduction
Antineoplastic drugs are used to treat more than
12.1 million individuals diagnosed with cancer
worldwide each year (Graeve, Mcgovern,
Alexander, Church, Ryan, and Polovich, 2017).
According to NIOSH, approximately 8 million
U.S. health care workers are potentially exposed
to a multitude of hazardous drugs in the
workplace (NIOSH, 2016). The drugs have been
detected in the urine of workers and on the floors
and counters of worksites (Randolph, 2012).
Chemotherapy
(antineoplastics)
drugs,
hormones, antivirals, as well as some
monoclonal antibodies and other miscellaneous
drugs are classified as a hazardous drug. They
are
used
to
treat
cancers,
human
immunodeficiency virus (HIV) and some
autoimmune diseases (Müller-Ramírez, Squibb
and Mcdiarmid, 2017). As new drugs are
developed to treat the numerous cancers and
other diseases, the health effects and the toxicity
of these drugs is not usually known. These drugs
must be handled using special precautions not
only by health care professionals, but by those
who work in these facilities as well. Although
the hazards associated with hazardous drugs are
recognized, there is not an acceptable exposure
limit to these drugs (Alehashem and Baniasadi,
2018).

Antineoplastic drugs
The health risks and toxicity associated with
antineoplastic drugs are well understood.
World Safety Journal. Vol. XXX. Issue 1

The International Agency for Research on
Cancer (IARC) has classified antineoplastic
drugs into three groups: Group 1 - carcinogenic
to humans; Group 2a - probably carcinogenic to
humans and: Group 2b - possibly carcinogenic
to humans (Graeve, Mcgovern, Alexande,
Church, Ryan, and Polovich, 2017). NIOSH
(2004) stated that there are approximately 140
agents that fit the definition of a hazardous drug.
Two-thirds of the hazardous drugs are
determined to be antineoplastic drugs. Terms
commonly known to describe the drugs are
“antineoplastic” and “cytotoxic”. “Hazardous
drugs” is a broader classification that can be used
to describe the drugs. The NIOSH Alert glossary
defines cytotoxic as “a pharmacologic
compound that is detrimental or destructive to
cells within the body” (NIOSH, 2004). The
International Society of Oncology Pharmacy
Practitioners (ISOPP) defines cytotoxic drugs as
“chemicals that affect cell growth and
proliferation, most of which either bind to
genetic material in the cell nucleus or affect
cellular proteins synthesis” (ISOPP, 2007).
Health care workers are exposed on a repeated
basis and experience side effects from these
drugs that have no benefit to these individuals
(Müller-Ramírez, Squibb and Mcdiarmid,
2017). Previously, safe handling guidelines have
only included cytotoxic or antineoplastic drugs
regarding health care worker exposure. Now, it
has been expanded to include all hazardous
drugs. There has been evidence that indicates
that health care workers are at risk from the
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effects of occupational exposure to hazardous
drugs.

Health effects
Prior studies have shown evidence of adverse
health effects associated with exposure to
antineoplastic drugs. These effects include acute
and chronic outcomes. Acute responses can be
nausea, skin rashes, hair loss, nasal sores,
abdominal pain, allergic reactions, and dizziness
(Müller-Ramírez, Squibb and Mcdiarmid,
2017). Chronic effects to hazardous drug
exposures can be delayed conception time,
spontaneous abortions, genotoxic changes, and
cancers (Foxhall, 2009). Hospital personnel
involved in preparation and administration of
antineoplastic drugs may be at risk if exposed to
these hazardous pharmaceuticals (Korczowska,
Jankowiak-Gracz, Sessink, and Grzeskowiak,
2013). If there is contamination in the
environment that healthcare workers are present,
we can assume that the workers are being
exposed as well (Foxhall, 2009). Small
exposures to such toxic drugs can have adverse
outcomes on the health of the healthcare worker.
Most exposures occur in hospitals and oncology
facilities during administration of the drugs and
the compounding process in the pharmacy. The
occupational risk for health care workers is
unacceptable (Graeve, Mcgovern, Alexande,
Church, Ryan, and Polovich, 2017).
Hazardous drugs can have multiple ways of
getting into the body of a healthcare worker.
They can be absorbed through inhalation, skin
contact, ingestion from hand-to-mouth and
injection. The main routes for exposure are
believed to be inhalation and ingestion.
Currently, it is not possible to establish a safe
occupational exposure limit to these drugs. Any
preventable occupational exposures should be
avoided if possible and follow the “As Low as
Reasonably Achievable” (ALARA) standard
(Müller-Ramírez, Squibb and Mcdiarmid,
2017).

Healthcare workers and risk control
The University of Minnesota researchers
conducted a study of 163 oncology health care
workers to determine factors that could
contribute to workplace exposure. The objective
of the study was to identify possible exposures,
as well as determining factors that direct the
safety behaviour of employees. The study also
conducted environmental hazardous drug wipe
World Safety Journal. Vol. XXX. Issue 1

sampling on surfaces present in the workplace.
There was surface contamination in areas that
personal protective equipment was not expected
to be used, which can lead to potential exposure
(Graeve, McGovern, Alexander, Church, Ryan,
and Polovich, 2017).
Many health care facilities that handle hazardous
drugs have adopted the hierarchy of controls.
The NIOSH Hierarchy of Controls has been
identified and can be applied to this health care
and the handling of hazardous drugs. These areas
covered in the hierarchy of controls include
elimination; substitution; engineering controls;
administrative controls; and personal protective
equipment. The basis behind the hierarchy of
controls is that it uses a top-down methodology
meaning that the most effective and protective
are at the top and less effective and protective are
at the bottom. Elimination of the hazard
(material or process) is the most effective yet
most difficult to implement in any process. In the
instance of hazardous drugs, elimination is not
possible, therefore diligent use of PPE, proper
use of engineering controls and implementation
of administrative control must be used.
Substitution has the same issues as elimination.
In healthcare, substitution with a less hazardous
drug is not possible. Patients are placed on
treatments that work for their disease.
Engineering controls are the first level that can
be used in health care settings because of their
designation to remove the hazard before it is in
contact with health care personnel. Finally,
administrative controls and personal protective
equipment (PPE) is used when the exposures are
not well controlled.
The first step is the engineering controls. When
a hazard cannot be eliminated, an engineering
control is recommended for use. In the case of
compounding hazardous drugs, it should always
be used for product and worker protection.
Examples of engineering controls that provide
worker and product protection are Class II and
III biological safety cabinets (BSC) that are
properly ducted with either a canopy or direct
connection to an exhaust or a compounding
aseptic containment isolator (CACI) that is
exhausted to the outside. These engineering
controls are placed within a controlled
cleanroom environment that is negative
pressure. The negative pressure cleanroom suite
has pressure in the range of -0.01 to -0.03 inches
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water column (in. w. c.) and exhausted to the
outside, as well. This is considered a secondary
engineering control (SEC) (USP Chapter <800>,
2017). These primary engineering controls are
often referred to as “hoods” in which the
compounding activities are performed. They
provide both product protection with an ISO
Class 5 environment inside of the biological
safety cabinet, as well as worker protection since
the engineering control provides containment.
Another level of protection to use both for
compounding and administration is the use of a
closed system transfer device (CTSD). This
system is needleless and attaches together to
transfer the hazardous drug between the vial to
IV bag without any exposure. It is an extra level
of protection if used within a BSC or CACI.
With regards to CTSDs, some facilities consider
them as a secondary engineering control used
within a primary engineering control when
compounding and mixing hazardous drugs, to
reduce the risk and exposure to the hazardous
drug. Others consider a CTSD as PPE (Mathias,
2019). The U.S. Pharmacopeia (USP)
recommends CTSD for compounding hazardous
drugs and defines them as mandatory for
administration of hazardous drugs (USP Chapter
800, 2017).
Next, the implementation of administrative
controls should be used to help with guidance on
processes within the health care facility. Some of
the administrative controls are to use medical
surveillance, training for employees who handle
these drugs, cleaning, and decontamination of
work surface sand disposal of hazardous drugs.
PPE used to compound and any waste from
compounding/ administration in the right waste
containers (black or yellow), disinfect and
deactivate the primary engineering controls
(BSCs or CACIs), store hazardous drugs alone
in a negative pressure room, define processes for
unpacking shipping totes that have hazardous
drugs, define a list of all hazardous drugs within
the facility, etc. The administrative controls
define processes that should be implemented
within the facility to lower the exposure risk
(Couch, West, and Niemeier, 2013).
A list of all the drugs used in the facility should
be compared to the list to the drugs on the
NIOSH List of Antineoplastic and Other
Hazardous Drugs in Healthcare Settings should
be created and made accessible to all the
World Safety Journal. Vol. XXX. Issue 1

personnel for staff that could possibly be in
contact with these drugs. It is important to
identify which departments and/or personnel
could potentially handle or contact the hazard
(ISOPP, 2007). Once the hazardous drugs in a
facility have been identified, an assessment of
risk should be completed by identifying the path
that the hazardous drugs follow from when they
enter the facility to when they leave as patient
waste, contaminated laundry, IV bags,
contaminated medical equipment etc. All
potential sources of exposure should be
identified. It is also important to identify all
individuals who have the potential contact or
handle hazardous drugs. Contamination of the
environmental can be determined by surface
sampling for hazardous drug residue. It is likely
that any area where hazardous drugs are used
could be contaminated by those drugs. The
hazardous drug residue wipe sampling is only
available for approximately 12 drugs that are
used because they can indicate exposure to any
of dozens of drugs the facility uses (ISOPP,
2007).
Personal protective equipment (PPE) is the last
area within the NIOSH hierarchy of controls.
With proper handling, as well as implementation
of proper PPE such as double gloving, use of
gloves rated by the American Society for Testing
and Materials (ASTM) for chemotherapy,
chemotherapy gowns made of polypropylene
which have taped seams and coated by
polyethylene on the outside to prevent liquids
from seepage through and onto the healthcare
worker, face shields to prevent splashing onto
the face and into the eyes and the use of
respirator protection, the incidence rate of
exposure is reduced (Couch, West, and
Niemeier, 2013). The amount of PPE donned is
dependent upon the drug and the procedure
involved with handling the hazardous drug
(Tomkins, 2015). CSTD systems can also be
considered PPE and provide protection to the
individuals handling these hazardous substances
(Mathias, Mackenzie, Toennis, and Connor
2019).
Studies have shown that more workers are
wearing gloves when handling hazardous drugs
since the initial safe handling guidelines were
implemented (Mathias, Mackenzie, Toennis,
and Connor 2019). However, a recent large
study of health care workers conducted by
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NIOSH (2016) found that one in seven of 2,069
reported not always using gloves while handling
hazardous agents. These studies determined that
a lower rate of use in PPE was reported. A study
of 165 nurses also found personal protective
equipment (PPE) use varied by activity, with the
lowest adherence to recommendations about the
handling of patient excreta (Mathias,
Mackenzie, Toennis, and Connor 2019).
Currently, healthcare facilities and pharmacies
that compound hazardous drugs are have a new
guideline to follow for both non-sterile and
sterile
products.
The
United
States
Pharmacopeia released a new guideline, Chapter
800, that was effective in most States, on July
1st, 2019. All chapters in the USP Compounding
Compendium under 1000 are enforceable by
state boards of pharmacy. This chapter outlines
safe handling, storage, compounding, room
requirements, engineering controls and PPE
requirements. The chapter was designed to be a
guide to help facilities minimize and manage the
drug exposures healthcare workers are exposed
to, as well as give design elements for the rooms
used for compounding. Previously, retail
pharmacies had to follow USP Chapter 795
regarding non-sterile compounding rules,
however, with the implementation of Chapter
800, it has now designated the same similar
elements for pharmacies that compound nonsterile hazardous drugs, such as estrogen and
testosterone creams, for hormone replacement
therapies.

Conclusions
In conclusion, it is necessary to keep healthcare
workers protected from hazardous drug
exposures. Use of the proper engineering
controls to keep the drugs contained when being
stored, compounded, and administered is crucial
to the health and well-being of these workers
who are exposed daily. Policies and procedures
designed around cleaning processes, proper PPE
needs, waste disposal, medical surveillance,
hazardous drug list, hazardous drug wipe
sampling and continuing education are designed
to help the individuals handling these drugs have
specific operating procedures for their facilities
needs that meet or exceed what should be done
to protect the workers. It is mission critical to
keep these workers safe. Without the
implementation of the controls, more
unnecessary exposures will occur which will
World Safety Journal. Vol. XXX. Issue 1

lead to more adverse outcomes to the workers
that are caring for some of the sickest patients.
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